Rituximab vs placebo
Improvement in 10‐metre walk time at 8 to 12 months1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
- Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 68 participantsModerate